US Stock MarketDetailed Quotes
BDTX Black Diamond Therapeutics
- 6.105
- +0.195+3.30%
Trading Jul 23 13:31 ET
343.51MMarket Cap-3677P/E (TTM)
6.270High5.887Low148.89KVolume5.890Open5.910Pre Close918.23KTurnover0.34%Turnover RatioLossP/E (Static)56.27MShares7.66052wk High3.29P/B268.80MFloat Cap1.62052wk Low--Dividend TTM44.03MShs Float46.250Historical High--Div YieldTTM6.49%Amplitude1.180Historical Low6.167Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Black Diamond Therapeutics Stock Forum
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology medicine company focusing on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Their main product candidate, BDTX-1535, is designed to treat brain-penetrant epidermal growth factor receptor (EGFR) mutations, notably in non-small cell lung cancer (NSCLC) and gli...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics presented promising clinical data on its lead candidate BDTX-1535 at the 2024 ASCO Annual Meeting. The Phase 1 dose escalation trial in recurrent glioblastoma (GBM) patients showed a favorable safety profile and encouraging anti-tumor activity, with sev...
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
No comment yet